-
2023-510054-16-00
4
2022-04-26
Primary Sjogren's syndrome
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2023-510432-36-00
4
2022-03-01
Acute Myeloid Leukemia with NPM1 mutation
-
2024-518304-53-00
5
2022-02-02
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-509406-30-00
10
2022-01-24
Patients with HER2-overexpressing advanced or metastatic gastric or ga
-
2023-510241-16-00
4
2021-12-03
Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-506256-25-00
5
2021-10-20
Active Psoriatic Arthritis
-
2024-518217-26-00
4
2021-10-20
Stage IV colorectal cancer patients with no evidence of disease (NED)
-
2024-512038-13-00
5
2021-09-16
Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
-
2024-513397-21-00
4
2021-09-16
Relapsed Multiple Myeloma
-
2023-508968-30-00
5
2021-09-08
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
-
2023-506368-14-00
5
2021-09-07
Systemic lupus erythematosus (SLE)
-
2024-516629-30-00
4
2021-06-24
Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube
-
2023-503916-33-00
5
2021-03-24
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-511637-35-00
5
2021-03-23
Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-516632-99-00
4
2021-03-17
Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian
-
2024-513296-41-00
4
2020-12-03
Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2022-502887-19-00
5
2020-08-18
Diffuse Large B-Cell Lymphoma
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer